Statistik Asas
| CIK | 1514183 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Silo Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 18, 2025 |
Silo Pharma, Inc. Up to 820,911 Shares of Upon Exercise of Certain Common Stock Purchase Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-281692 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated April 3, 2025) Silo Pharma, Inc. Up to 820,911 Shares of Upon Exercise of Certain Common Stock Purchase Warrants This prospectus supplement supplements the prospectus dated April 5, 2025 (the “Prospectus”) of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), which forms a part of our |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Exa |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 5, 2025 |
Exhibit 99.1 Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 29, 2025 |
Asset Purchase Agreement, dated July 29, 2025, between the Company and MAVS Holdings LLC. Exhibit 10.1 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made between MAVS HOLDINGS LLC, a Delaware limited liability corporation (“Mavs”) (the “Assignor”), and SILO PHARMA. INC., a Nevada corporation (“Assignee”), and is effective as of the date of the last signature below (the “Effective Date”). WHEREAS, Assignor has developed the Software, and exclusively owns a |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 10, 2025 |
Exhibit 10.1 Termination, Commercial Evaluation License, and Option Agreement between University of Maryland, Baltimore and Silo Pharma, Inc. University Docket No.: KM-2016-101 CONFIDENTIAL Termination, Commercial Evaluation License, and Option Agreement This Termination, Commercial Evaluation License, and Option Agreement (“Agreement”) is effective as of June 30, 2025 (“Effective Date”), and is m |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 16, 2025 |
Form of Series A-1 Common Warrant. Exhibit 4.2 SERIES A-1 COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| May 16, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 15, 2025, between Silo Pharma, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| May 16, 2025 |
Form of Placement Agent Warrant. Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Issue Date: May 16, 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| May 16, 2025 |
Exhibit 10.2 LOCK-UP AGREEMENT , 2025 H.C. Wainwright & Co., LLC as placement agent in the Offering (as defined below) Re: Offering (as defined below) by Silo Pharma, Inc. (the “Company”) Ladies and Gentlemen: The undersigned irrevocably agrees with the Company that, from the date hereof until sixty (60) days following the closing of the Company’s offering of registered securities pursuant to an e |
|
| May 16, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-286777 PROSPECTUS Silo Pharma, Inc. 2,723,336 Shares of Common Stock 3,333,338 Series A-1 Warrants to Purchase Shares of Common Stock 3,333,338 Series A-2 Warrants to Purchase Shares of Common Stock 610,002 Pre-Funded Warrants to Purchase Shares of Common Stock Placement Agent Warrants to Purchase up to 250,000 Shares of Common Stock Up to 7,56 |
|
| May 16, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 16, 2025 |
Form of Series A-2 Common Warrant. Exhibit 4.3 SERIES A-2 COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES A-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| May 16, 2025 |
Silo Pharma Announces Pricing of $2 Million Public Offering Exhibit 99.1 Silo Pharma Announces Pricing of $2 Million Public Offering SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu |
|
| May 16, 2025 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Initial Exercise Date: May 16, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| May 16, 2025 |
Silo Pharma Announces Closing of $2 Million Public Offering Exhibit 99.2 Silo Pharma Announces Closing of $2 Million Public Offering SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in li |
|
| May 12, 2025 |
May 12, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Ex |
|
| May 9, 2025 |
Exhibit 10.46 Execution Version May 6, 2025 STRICTLY CONFIDENTIAL Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, Florida 34236 Attn: Eric Weisblum, Chief Executive Officer Dear Mr. Weisblum: Reference is made to the engagement letter (the “Engagement Letter”), dated March 5, 2025, as amended on April 8, 2025, by and between Silo Pharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025. As filed with the Securities and Exchange Commission on May 9, 2025. Registration No. 333-286777 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation or or |
|
| April 30, 2025 |
April 30, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jessica Dickerson Re: Silo Pharma, Inc. Form S-1 Registration Statement Filed April 25, 2025 File No. 333-286777 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on April 28, 2025, in which we requested for acceler |
|
| April 29, 2025 |
Exhibit 10.45 Execution Version April 8, 2025 STRICTLY CONFIDENTIAL Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, Florida 34236 Attn: Eric Weisblum, Chief Executive Officer Dear Mr. Weisblum: Reference is made to the engagement letter (the “Engagement Letter”), dated March 5, 2025, by and between Silo Pharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025. As filed with the Securities and Exchange Commission on April 29, 2025. Registration No. 333-286777 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation or |
|
| April 29, 2025 |
Engagement Letter dated March 5, 2025 between Silo Pharma, Inc. and H.C. Wainwright & Co., LLC Exhibit 10.44 Execution Version March 5, 2025 STRICTLY CONFIDENTIAL Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, Florida 34236 Attn: Eric Weisblum, Chief Executive Officer Dear Mr. Weisblum: This letter agreement (this “Agreement”) constitutes the agreement between Silo Pharma, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusi |
|
| April 28, 2025 |
April 28, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| April 25, 2025 |
Form of Securities Purchase Agreement* Exhibit 10.43 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Silo Pharma, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| April 25, 2025 |
Form of Placement Agent Warrant* Exhibit 4.9 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Shareholder Ap |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025. As filed with the Securities and Exchange Commission on April 25, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation or organization) (Primary S |
|
| April 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) SILO PHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Title of each Class of Securities To be Registered Amount to be registered (1) Proposed maximum Offering price per share (2) (3)(4) Proposed maximum aggregate Offering price (1)(2) Amount of registration fee (3) |
|
| April 25, 2025 |
Form of Common Stock Purchase Warrant* Exhibit 4.7 Exhibit A-1 SERIES [A-1][A-2] COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES [A-1][A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| April 25, 2025 |
Exhibit 4.8 Exhibit A-2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| April 11, 2025 |
As confidentially submitted to the Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on April 11, 2025. |
|
| April 4, 2025 |
Silo Pharma, Inc. Up to 820,911 Shares of Upon Exercise of Certain Common Stock Purchase Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-281692 PROSPECTUS Silo Pharma, Inc. Up to 820,911 Shares of Upon Exercise of Certain Common Stock Purchase Warrants This prospectus relates to the offer and resale of up to an aggregate of 820,911 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), consi |
|
| March 28, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Silo Pharma, Inc. (“the Company”) had one class of security registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description of |
|
| March 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2025 As filed with the U.S. Securities and Exchange Commission on March 28, 2025 Registration No. 333-281692 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of inc |
|
| March 28, 2025 |
Exhibit 19.1 Effective Date: June 14, 2024 SILO PHARMA, INC. AMENDED AND RESTATED INSIDER TRADING COMPLIANCE PROGRAM In order to take an active role in the prevention of insider trading violations by its officers, directors, employees and other related individuals, the Board of Directors (the “Board”) of Silo Pharma, Inc. (the “Company”) has adopted the policies and procedures described in this Me |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41512 SILO PHARMA, INC (Name of Registrant as Specifi |
|
| March 10, 2025 |
Exhibit 99.1 NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS Investor Presentation March 2025 FORWARD - LOOKING STATEMENTS This presentation contains “forward - looking statements” within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expec |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 7, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 2, 2025 |
Exhibit 99.1 Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain ● IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approval ● SP-26 ketamine implants nearing first animal studies SARASOTA, FL, January 2, 2025 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) ( |
|
| January 2, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. |
|
| November 12, 2024 |
Exhibit 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (this “Amendment”) to Employment Agreement is hereby entered into on November 11, 2024 by and between SILO Pharma, Inc., a Nevada corporation (the “Company”) and Daniel Ryweck (“Executive”). The Company and Executive are collectively referred to herein as the “Parties”. WITNESSETH: WHEREAS, the Company and Executive are pa |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 10, 2024 |
Exhibit 99.1 NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS Investor Presentation September 2024 FORWARD - LOOKING STATEMENTS This presentation contains “forward - looking statements” within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “e |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| September 4, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-281692 PROSPECTUS Silo Pharma, Inc. Up to 820,911 Shares of Common Stock Issuable Upon Exercise of Certain Common Stock Purchase Warrants This prospectus relates to the offer and resale of up to an aggregate of 820,911 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, |
|
| August 29, 2024 |
Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, FL 34236 Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, FL 34236 August 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Silo Pharma, Inc. Registration Statement on Form S-1 File No. 333-281692 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations unde |
|
| August 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Silo Pharma, Inc. |
|
| August 21, 2024 |
As filed with the U.S. Securities and Exchange Commission on August 21, 2024 As filed with the U.S. Securities and Exchange Commission on August 21, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation or organization) (Prim |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Exa |
|
| July 31, 2024 |
Silo Pharma, Inc. Up to 1,043,739 Shares of Upon Exercise of Certain Common Stock Purchase Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-280855 PROSPECTUS Silo Pharma, Inc. Up to 1,043,739 Shares of Upon Exercise of Certain Common Stock Purchase Warrants This prospectus relates to the offer and resale of up to an aggregate of 1,043,739 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), c |
|
| July 26, 2024 |
SILO / Silo Pharma, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment SC 13G 1 ea021007301-13gintrasilo.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silo Pharma, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82711P201 (CUSIP Number) July 18, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| July 26, 2024 |
EX-99.1 2 ea021007301ex99-1silo.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agre |
|
| July 26, 2024 |
Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, FL 34236 Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, FL 34236 July 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Patrick Fullem Re: Silo Pharma, Inc. Registration Statement on Form S-1 File No. 333- 280855 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations unde |
|
| July 25, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 25, 2024 As filed with the U.S. Securities and Exchange Commission on July 25, 2024 Registration No. 333-280855 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation |
|
| July 22, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 22, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 18, 2024, between Silo Pharma, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| July 22, 2024 |
Exhibit 99.1 Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today |
|
| July 22, 2024 |
Exhibit 99.2 Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatme |
|
| July 22, 2024 |
763,638 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276658 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 30, 2024) 763,638 Shares of Common Stock We are offering 763,638 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement and the accompanying prospectus to several institutional investors. The purchase price of each share of common stock to the pur |
|
| July 22, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 22, 2024 |
Exhibit 10.2 LOCK-UP AGREEMENT July , 2024 Re: Securities Purchase Agreement, dated as of July , 2024 (the “Purchase Agreement”), between Silo Pharma, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings s |
|
| July 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Silo Pharma, Inc. |
|
| July 17, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 17, 2024 As filed with the U.S. Securities and Exchange Commission on July 17, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 2834 27-3046338 (State or other jurisdiction of incorporation or organization) (Primar |
|
| July 8, 2024 |
Extensive Issued and Pending IP Patent Applications Acquired with License Agreement Exhibit 99.1 Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders Extensive Issued and Pending IP Patent Applications Acquired with License Agreement SARASOTA, FL, July 08, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing |
|
| July 8, 2024 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT This exclusive license agreement (the “Agreement”) is dated June 28, 2024, (the “Effective Date”) and is between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York |
|
| July 8, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 27, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 27, 2024 |
Fourth Amendment to Master License Agreement Exhibit 10.1 FOURTH AMENDMENT TO MASTER LICENSE AGREEMENT This Fourth Amendment to Master License Agreement Fourth Amendment ) is effective as of the date of last signature below and is made by and between the UNIVERSITY OF MARYLAND, BALTIMORE (“University”), a public university that is part of the University System of Maryland (which is a public corporation and an instrumentality of the State of |
|
| June 13, 2024 |
SILO / Silo Pharma, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment SC 13G 1 ea0207788-13gintrasilo.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Silo Pharma, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 82711P201 (CUSIP Number) June 4, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| June 13, 2024 |
EX-99.1 2 ea020778801ex99-1silo.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agre |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 6, 2024 |
Exhibit 4.2 EXHIBIT A-1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| June 6, 2024 |
Exhibit 4.1 EXHIBIT A-2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Silo Pharma, Inc. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da |
|
| June 6, 2024 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 6, 2024 |
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SARASOTA, FL, June 5, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today ann |
|
| June 6, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276658 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 30, 2024) 883,395 Shares of Common Stock Pre-Funded Warrants to Purchase 34,037 Shares of Common Stock (and the shares of Common Stock underlying the Pre-Funded Warrants) We are offering 883,395 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus suppleme |
|
| June 6, 2024 |
Exhibit 10.2 LOCK-UP AGREEMENT June 4, 2024 Re: Securities Purchase Agreement, dated as of June 4, 2024 (the “Purchase Agreement”), between Silo Pharma, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings |
|
| June 6, 2024 |
Exhibit 99.2 Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments |
|
| June 6, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 4, 2024, between Silo Pharma, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| June 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 4, 2024 |
Exhibit 99.1 Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 4, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Ex |
|
| April 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 25, 2024 |
Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name Jurisdiction of Incorporation/Formation Silo Pharma, Inc. Florida |
|
| March 25, 2024 |
Silo Pharma, Inc. Clawback Policy Exhibit 97.1 SILO PHARMA, INC. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of Silo Pharma, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore |
|
| March 25, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Silo Pharma, Inc. (“the Company”) had one class of security registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description of |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41512 SILO PHARMA, INC (Name of Registrant as Specifi |
|
| February 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 1, 2024 |
Exhibit 99.1 Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 1, 2024 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev |
|
| January 26, 2024 |
Silo Pharma, Inc. 677 N. Washington Blvd. Sarasota, Florida 34236 January 26, 2024 Silo Pharma, Inc. 677 N. Washington Blvd. Sarasota, Florida 34236 January 26, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Bradley Ecker Re: Silo Pharma, Inc. Registration Statement on Form S-3 File No. 333- 276658 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, |
|
| January 25, 2024 |
EX-99.1 2 ea192209ex99-1silo.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the common shares of Silo Pharma, Inc. and further agree that |
|
| January 25, 2024 |
SILO / Silo Pharma, Inc. / Reda Joseph - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea192209-13ga2redasilo.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) Silo Pharma, Inc. (Name of |
|
| January 25, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 25, 2024 As filed with the U.S. Securities and Exchange Commission on January 25, 2024 Registration No. 333-276658 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Nevada 27-3046338 (State or other jurisdiction of (I.R.S. Employe |
|
| January 23, 2024 |
Form of Subordinated Indenture Exhibit 4.3 SILO PHARMA, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 6 S |
|
| January 23, 2024 |
Exhibit 4.1 |
|
| January 23, 2024 |
Exhibit 4.2 SILO PHARMA, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 Section |
|
| January 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) SILO PHARMA, INC. |
|
| January 23, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 23, 2024 As filed with the U.S. Securities and Exchange Commission on January 23, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Nevada 27-3046338 (State or other jurisdiction of (I.R.S. Employer incorporation or organi |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 20, 2023 |
Exhibit 3.3 |
|
| December 20, 2023 |
Exhibit 3.1 |
|
| December 20, 2023 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Description of Common Stock The following description of the common stock, par value $0.0001 per share (“Common Stock”) of Silo Pharma, Inc., a Nevada corporation (the “Company”) is a summary and does not purport to be complete. It is subject to and qualified in its entir |
|
| December 20, 2023 |
Exhibit 3.4 BYLAWS OF SILO PHARMA, INC. (hereinafter called the “Corporation”) ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation shall be established and maintained at the office of SPI Agent Solutions, Inc., at 4625 W. Nevso Drive, Suites 2, in the City of Las Vegas, County of Clark, in the State of Nevada. SPI Agent Solutions, Inc. shall be the registered |
|
| December 20, 2023 |
Exhibit 3.2 |
|
| December 20, 2023 |
Exhibit 2.1 PLAN OF CONVERSION OF SILO PHARMA, INC. A DELAWARE CORPORATION INTO SILO PHARMA, INC., A NEVADA CORPORATION THIS PLAN OF CONVERSION, dated as of December 19, 2023 (including all of the Exhibits attached hereto, this “Plan”), is hereby adopted by Silo Pharma, Inc., a Nevada corporation, in order to set forth the terms, conditions and procedures governing the conversion of Silo Pharma, I |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| December 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| December 5, 2023 |
Exhibit 3.1 |
|
| December 4, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2023 |
Third Amendment to Master License Agreement Exhibit 10.1 Third Amendment To Master License Agreement This Third Amendment to Master License Agreement (“Third Amendment”) is effective as of the date of last signature below and is made by and between the UNIVERSITY OF MARYLAND, BALTIMORE (“University”), a public university that is part of the University System of Maryland (which is a public corporation and an instrumentality of the State of M |
|
| November 14, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54872 27-3046338 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 31, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Exa |
|
| June 29, 2023 |
Fifth Amendment To Commercial Evaluation and License Agreement Exhibit 99.1 Fifth Amendment To Commercial Evaluation and License Agreement This Fifth Amendment to Commercial Evaluation and License Agreement (“Fifth Amendment”) is effective as of the date of the last signature on the signature page between the UNIVERSITY OF MARYLAND, BALTIMORE (“University”), a public university that is part of the University System of Maryland (which is a public corporation a |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. (Ex |
|
| March 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 27, 2023 |
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia Exhibit 99.1 Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (the “Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with p |
|
| March 24, 2023 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Silo Pharma, Inc. (“the Company”) had one class of security registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description of |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41512 SILO PHARMA, INC (Name of Registrant as Specifi |
|
| March 24, 2023 |
List of Subsidiaries of Silo Pharma, Inc. Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name Jurisdiction of Incorporation/Formation Silo Pharma, Inc. Florida |
|
| February 15, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 15, 2023 |
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s Exhibit 99.1 Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychede |
|
| February 14, 2023 |
SILO / Silo Pharma Inc / Reda Joseph - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea123456-13ga1redasilo.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) Silo Pharma, Inc. (Name of |
|
| February 3, 2023 |
Silo Pharma Announces Expansion of Intellectual Property Portfolio Exhibit 99.1 Silo Pharma Announces Expansion of Intellectual Property Portfolio Silo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeu |
|
| February 3, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| January 31, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| January 31, 2023 |
Silo Pharma Announces Stock Repurchase Program Exhibit 99.1 Silo Pharma Announces Stock Repurchase Program ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2023 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2022 |
Exhibit 99.1 Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter |
|
| November 16, 2022 |
SILO / Silo Pharma Inc / Reda Joseph - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Silo Pharma, Inc. (Name of Issuer) Common Shares, par value $0.0001 per share (Title of Class of Securities) (CUSI |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41512 SILO PHARMA, INC. |
|
| October 18, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of this 12th day of October, 2022 (the ?Effective Date?), by and between Silo Pharma Inc, a Delaware corporation with offices at 60 Sylvan Ave, Suite 3160, Englewood Cliffs NJ 07632 (the ?Corporation?), and Eric Weisblum, an individual residing at 41 Owatonna St, Haworth NJ 07641 (the ?Executi |
|
| October 18, 2022 |
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics Exhibit 99.2 Silo Pharma extends research pact for Alzheimer?s and Stress Induced Anxiety Therapeutics Silo and Columbia University continue research on SPC-14 for Alzheimer?s and SPC-15 for Stress Induced Disorders ENGLEWOOD CLIFFS, NJ , October. 18, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (NASDAQ: SILO) (?the Company?), a developmental stage biopharmaceutical company focused on merging traditi |
|
| October 18, 2022 |
Exhibit 10.3 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement is made and entered into as of October 12, 2022 (the ?Effective Date?), by and between Daniel Ryweck (the ?Employee?) and Silo Pharma, Inc., a Delaware corporation (the ?Company?), the Corporation and the Employee are collectively referred to herein as the ?Parties.? WITNESSETH WHEREAS, the Corporatio |
|
| October 18, 2022 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT This First Amendment to Sponsored Research Agreement (the ?First Amendment?) made and entered into as of , 2022 (the ?First Amendment Effective Date?), by and betwe |
|
| October 18, 2022 |
Exhibit 99.1 Corporate Presentation Nasdaq: SILO 1 Fall 2022 Nasdaq: SILO | | | | | | | | | | | Statement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ?could?, ?believe?, ?anticipate?, ?intend?, ?estimate?, ?expect?, ?may?, |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2022 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| September 30, 2022 |
Exhibit 4.1 FORM OF REPRESENTATIVE?S WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT |
|
| September 30, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into as of September 28, 2022 (the ?Effective Date?), by and between Daniel Ryweck (the ?Employee?) and Silo Pharma, Inc., a Delaware corporation (the ?Company?). WHEREAS, the Company desires to employ the Employee on the terms and conditions set forth herein; and WHEREAS, the Employee desires to be e |
|
| September 30, 2022 |
Exhibit 1.1 1,000,000 SHARES of Common Stock of SILO PHARMA, INC. UNDERWRITING AGREEMENT September 26, 2022 Laidlaw & Company (UK) Ltd. As the Representative of the several underwriters, if any, named in Schedule I hereto 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: The undersigned, Silo Pharma, Inc., a company incorporated under the laws of Delaware (collectively with its |
|
| September 30, 2022 |
Exhibit 99.2 Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter?s Over-Allotment Option ENGLEWOOD CLIFFS, NJ ? September 30, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the |
|
| September 30, 2022 |
Exhibit 99.1 Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol ?SILO? ENGLEWOOD CLIFFS, NJ ? Sept. 27, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focus |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Silo Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41512 27-3046338 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 28, 2022 |
Silo Pharma, Inc. 1,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333.261532 PROSPECTUS Silo Pharma, Inc. 1,000,000 Shares of Common Stock This prospectus relates to the sale by Silo Pharma, Inc. (the “Company” or “Silo Pharma”) of 1,000,000 shares of common stock of (the “Common Stock”), at a public offering price of $5.00 per share of common stock. Our common stock has been approved for listing on The Nasdaq Ca |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 27-3046338 (State of incorporation or organization) (IRS Employer Identification No.) 560 Sylvan Avenue, Suite 31 |
|
| September 22, 2022 |
SILO PHARMA, INC. 560 Sylvan Ave, Suite 3160 Englewood Cliffs NJ 07632 September 22, 2022 CORRESP 1 filename1.htm SILO PHARMA, INC. 560 Sylvan Ave, Suite 3160 Englewood Cliffs NJ 07632 September 22, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Greg Herbers Re: Silo Pharma, Inc. Registration Statement on Form S-1 (File No. 333-261532) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations un |
|
| September 22, 2022 |
September 22, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 20, 2022 |
As filed with the Securities and Exchange Commission on September 20, 2022. As filed with the Securities and Exchange Commission on September 20, 2022. Registration Statement No. 333-261532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 27-3046338 (State or other jurisdiction of |
|
| September 15, 2022 |
Exhibit 99.1 Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq ENGLEWOOD CLIFFS, NJ ? September 15, 2022 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (OTCQB: SILO) (?the Company?), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it will effect a 1-fo |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organi |
|
| September 15, 2022 |
EX-3.1 2 ea165863ex3-1silopharma.htm CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF SILO PHARMA, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT to CERTIFICATE OF INCORPORATION of SILO PHARMA, INC. SILO PHARMA, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corp |
|
| September 9, 2022 |
As filed with the Securities and Exchange Commission on September 8, 2022. As filed with the Securities and Exchange Commission on September 8, 2022. Registration Statement No. 333-261532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 27-3046338 (State or other jurisdiction of i |
|
| September 9, 2022 |
Form of Representative Warrant (included in Exhibit 1.1) Exhibit 1.1 [*] SHARES of Common Stock of SILO PHARMA, INC. UNDERWRITING AGREEMENT [*], 2022 Laidlaw & Company (UK) Ltd. As the Representative of the several underwriters, if any,named in Schedule I hereto 521 Fifth Avenue, 12th Floor New York, NY 10175 Ladies and Gentlemen: The undersigned, Silo Pharma, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, i |
|
| August 29, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) SILO PHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Title of each Class of Securities To be Registered Amount to be registered (1) Proposed maximum Offering price per share (2) (3)(4) Proposed maximum aggregate Offering price (1)(2) Amount of registration fee (3) |
|
| August 29, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022. As filed with the Securities and Exchange Commission on August 26, 2022. Registration Statement No. 333-261532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 27-3046338 (State or other jurisdiction of inc |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54872 SILO PHARMA, INC. (Exa |
|
| July 25, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022. As filed with the Securities and Exchange Commission on July 22, 2022. Registration Statement No. 333-261532 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 27-3046338 (State or other jurisdiction of incor |
|
| July 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) SILO PHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Title of each Class of Securities To be Registered Amount to be registered (1) Proposed maximum Offering price per share (2) (3)(4) Proposed maximum aggregate Offering price (1)(2) Amount of registration fee (3) |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54872 SILO PHARMA, INC. (Ex |
|
| March 28, 2022 |
Description of the Registrant’s Securities. EX-4.1 2 f10k2021ex4-1silopharma.htm DESCRIPTION OF THE REGISTRANT'S SECURITIES Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Silo Pharma, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its co |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54872 SILO PHARMA, INC (Name of Registrant as Specifi |
|
| March 28, 2022 |
List of Subsidiaries of Silo Pharma, Inc. EX-21.1 3 f10k2021ex21-1silopharma.htm SUBSIDIARIES Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name Jurisdiction of Incorporation/Formation Silo Pharma, Inc. Florida |
|
| March 11, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File Number) (IRS Employer incorporation or or |
|
| March 7, 2022 |
DEFA14A 1 ea156556-defa14asilopharma.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of incorporation or organization) (Commission File Number) (IR |
|
| February 14, 2022 |
DEF 14A 1 ea155687-def14asilopharma.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File Number) (IRS Employer incorporation or |
|
| December 7, 2021 |
As filed with the Securities and Exchange Commission on December 7, 2021. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SILO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 27-3046338 (State or other jurisdiction of incorporation or organizati |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54872 SILO PHARMA, INC. |
|
| October 27, 2021 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SPONSORED RESEARCH AGREEMENT AGREEMENT (Agreement), effective as of , between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (?Columbia?), and Silo Pharma Inc., a Delaware cor |
|
| October 27, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54872 27-3046338 (State or other jurisdiction of incorporation) (Commission File |
|
| October 27, 2021 |
Exhibit 99.1 Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer?s Disease Agreement Provides for Option to License Alzheimer?s Therapeutic Englewood Cliffs NJ, October, 2021 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic |
|
| September 27, 2021 |
Form of Stock Purchase Agreement Exhibit 10.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) entered into this day of September 2021, by and between Silo Pharma, Inc. (the ?Seller?) [ ](the ?Purchaser?) (collectively, the ?Parties?). RECITALS WHEREAS, the Seller is the owner of shares of common stock $0.0001 par value per share (?Common Stock?) of DatChat, Inc. (the ?Company?); and WHEREAS, the Purchaser |
|
| September 27, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2021 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 000-54872 27-3046338 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organizat |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54872 SILO PHARMA, INC. (Exa |
|
| July 12, 2021 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (?Agreement?) is effective as of the last date of signature on the signature page below (?Effective Date?) by and between the University of Maryland, |
|
| July 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organization |
|
| July 12, 2021 |
Exhibit 10.2 FIRST AMENDMENT TO COMMERCIAL EVALUATION AND LICENSE AGREEMENT This First Amendment to Commercial Evaluation and License Agreement (?First Amendment?) is effective as of the date of the last signature on the signature page between the UNIVERSITY OF MARYLAND, BALTIMORE (?University?), a public university that is part of the University System of Maryland (which is a public corporation a |
|
| July 12, 2021 |
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore EX-99.1 4 ea144103ex99-1silopharma.htm PRESS RELEASE, DATED JULY 12, 2021 Exhibit 99.1 Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis Next steps include targeted approach to delivering Psychedelics including Psilocybin and Ketamine Silo Pharma, Inc. (OTC QB: SILO |
|
| June 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organization |
|
| June 7, 2021 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (?Agreement?), effective as of June 1, 2021 (?Effective Date?), is made by and between Silo Pharma having its principal offices at 560 Sylvan Avenue, |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54872 SILO PHARMA, INC. (Ex |
|
| May 17, 2021 |
List of Subsidiaries of Silo Pharma, Inc. Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name Jurisdiction of Incorporation/Formation Silo Pharma, Inc. Florida |
|
| May 17, 2021 |
10-K/A 1 f10k2020a1silopharmainc.htm AMENDMENT NO. 1 TO FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr |
|
| May 17, 2021 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Silo Pharma, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description of Com |
|
| April 28, 2021 |
Exhibit 99.1 Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI?s Z-pod? technology for the transdermal time released delivery of therapeutics Sustained Transdermal Delivery Method May Be Key for Alzheimer?s and Parkinson?s Patients with Dysphagia (difficulty swallowing) Englewood Cliffs, NJ, April 28, 2021 (GLO |
|
| April 28, 2021 |
EX-10.1# 2 ea140001ex10-1silopharmainc.htm JOINT VENTURE AGREEMENT, DATED APRIL 22, 2021, BY AND BETWEEN THE COMPANY AND ZYLO THERAPEUTICS, INC. Exhibit 10.1# [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. JOINT VENTURE AGREEMENT This Joint Venture Agreement (the “Agreeme |
|
| April 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 ea140001-8ksilopharmainc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commiss |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organizati |
|
| April 16, 2021 |
Exhibit 10.1 AMENDMENT NO. 1 TO PATENT LICENSE AGREEMENT This Amendment No. 1 (this ?Amendment?) to the Patent License Agreement (as defined below) is made and entered into as of April 12, 2021, by and among Silo Pharma Inc., a Delaware corporation, Silo Pharma, Inc., a Florida corporation, and their Affiliates/Subsidiaries, (the ?Licensor?), on the one hand and AIkido Pharma Inc., a Delaware corp |
|
| April 13, 2021 |
Silo Pharma, Inc. 28,506,646 Shares of Common Stock 424B3 1 ea139375-424b3silopharma.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-253170 PROSPECTUS Silo Pharma, Inc. 28,506,646 Shares of Common Stock This prospectus relates to the resale by certain selling stockholders of Silo Pharma, Inc., a Delaware corporation (the “Company”) identified in this prospectus of up to 28,506,646 shares (the “Resale Shares”) of our common stoc |
|
| April 8, 2021 |
CORRESP 1 filename1.htm SILO PHARMA, INC. 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 April 8, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Sisi Cheng Re: Silo Pharma, Inc. Registration Statement on Form S-1 Filed April 7, 2021 File No. 333-253170 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and |
|
| April 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 ea139213-8ksilopharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission |
|
| April 7, 2021 |
Exhibit 99.1 Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology Agreement to explore the use of Silo Pharma?s Novel Peptide Englewood Cliffs, NJ, April 7, 2021 (GLOBE NEWSWIRE) - Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has finalized an agre |
|
| April 7, 2021 |
As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. |
|
| April 7, 2021 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Sublicense AGREEMENT This Sublicense License Agreement (?Agreement?) is effective as of the date of the last signature on the signature page (?Effective Date?) and is made by and between Silo Pharma, Inc., a Dela |
|
| March 29, 2021 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Silo Pharma, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description of Com |
|
| March 29, 2021 |
List of Subsidiaries of Silo Pharma, Inc. Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name Jurisdiction of Incorporation/Formation Silo Pharma, Inc. Florida |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54872 SILO PHARMA, INC. (Exact name |
|
| March 12, 2021 |
8-K 1 ea137577-8ksilopharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission |
|
| March 12, 2021 |
Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?SILO PHARMA, INC.?, FILED IN THIS OFFICE ON THE TENTH DAY OF MARCH, A.D. 2021, AT 1:50 O?CLOCK P.M. 5251646 8100 SR# 20210860706 Authentication: 202704537 Date: 03-11-21 You may verify this cert |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 16, 2021 |
As filed with the Securities and Exchange Commission on February 16, 2021 Registration No. |
|
| February 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 ea135663-8ksilopharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commiss |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| February 16, 2021 |
Exhibit 21.1 List of Subsidiaries of Silo Pharma, Inc. Name State of Organization or Incorporation Silo Pharma, Inc. Florida |
|
| February 16, 2021 |
EX-10.2 3 ea135663ex10-2silopharma.htm LETTEROF INTENT, DATED FEBRUARY 12, 2021, BY AND BETWEEN THE COMPANY AND AIKIDO PHARMA, INC Exhibit 10.2 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. February 12, 2021 Eric Weisblum Chief Executive Officer Silo Pharma, Inc. 560 Syl |
|
| February 16, 2021 |
EX-10.1 2 ea135663ex10-1silopharma.htm MASTER LICENSE AGREEMENT, DATED FEBRUARY 12, 2021, BY AND BETWEEN THE COMPANY AND THE UNIVERSITY OF MARYLAND, BALTIMORE Exhibit 10.1 Master License Agreement between University of Maryland, Baltimore and Silo Pharma, Inc. OTT Docket No.: KM-2016-101 CONFIDENTIAL Master License Agreement Table Of Contents Article 1. BACKGROUND 1 Article 2. DEFINITIONS 1 Articl |
|
| February 12, 2021 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organi |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organiza |
|
| February 10, 2021 |
PRE 14A 1 ea135083-pre14asilopharma.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for U |
|
| February 10, 2021 |
EX-3.1 2 ea135066ex3-1silopharma.htm CERTIFICATE OF DESIGNATION OF SERIES C CONVERTIBLE PREFERRED STOCK Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “SILO PHARMA, INC.”, FILED IN THIS OFFICE ON THE NINTH DAY OF FEBRUARY, A.D. 2021, AT 6:2 |
|
| February 10, 2021 |
EX-10.4 6 ea135066ex10-4silopharma.htm FORM OF LOCK-UP AGREEMENT, DATED AS OF FEBRUARY 9, 2021 Exhibit 10.4 LOCK-UP AGREEMENT February , 2021 Silo Pharma, Inc. Re: Securities Purchase Agreement, dated as of February , 2021 (the “Purchase Agreement”), between Silo Pharma, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and G |
|
| February 10, 2021 |
EX-99.1 7 ea135066ex99-1silopharma.htm PRESS RELEASE, DATED FEBRUARY 10, 2021 Exhibit 99.1 Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space Englewood Cliffs, NJ, Feb. 09, 2021 (GLOBE NEWSWIRE) - Silo Pharma, Inc. |
|
| February 10, 2021 |
EX-10.3 5 ea135066ex10-3silopharma.htm FORM OF REGISTRATION RIGHTS AGREEMENT, DATED AS OF FEBRUARY 9, 2021, BETWEEN SILO PHARMA, INC. AND THE SIGNATORIES THERETO Exhibit 10.3 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February , 2021, between Silo Pharma, Inc., a Delaware corporation (the “Company”), and each of the |
|
| February 10, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February , 2021 between Silo Pharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| February 10, 2021 |
Exhibit 10.2 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commission File (IRS Employer incorporation or organiza |
|
| January 28, 2021 |
Exhibit 10.1 SILO PHARMA, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Silo Pharma, Inc. 2020 Omnibus Equity Incentive Plan. The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and success of |
|
| January 28, 2021 |
EX-10.2 3 ea134100ex10-2silopharma.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JANUARY 18, 2021, BY AND BETWEEN THE COMPANY AND ERIC WEISBLUM Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (this “Amendment”) to Employment Agreement is hereby entered into on January 18, 2021 and effective as of January 1, 2021 by and between SILO Pharma, Inc., a Delaware corporatio |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5) SILO PHARMA, INC. (Name of Issuer) COMMON STOCK, $.0001 PAR VALUE (Title of Class of Securities) 82711P102 (CUSIP Number) December 31, 2019 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to |
|
| January 11, 2021 |
EX-10.1 2 ea132847ex10-1silo.htm PATENT LICENSE AGREEMENT BY AND AMONG THE COMPANY AND SILO PHARMA, INC., A DELAWARE CORPORATION AND THEIR AFFILIATES AND SUBSIDIARIES AND AIKIDO PHARMA INC. Exhibit 10.1 Patent License Agreement This Patent License Agreement (this “Agreement”) is effective as of the date of the last signature on the signature page (the “Effective Date”), and is made by and between |
|
| January 11, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 ea132847-8ksilopharma.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 SILO PHARMA, INC. (Name of registrant in its charter) Delaware 000-54872 27-3046338 (State or jurisdiction of (Commissio |
|
| January 11, 2021 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (“Agreement”) is effective as of the last date of signature on the signature page below (“Effective Date”) by and between the University of Maryland, |
